Analyse the risk factors for producing anti-HLA antibodies in patients with hematological diseases
Journal Title: Chinese Journal of Blood Transfusion - Year 2024, Vol 37, Issue 2
Abstract
Objective To explore the risk factors for the production of anti-HLA antibodies in patients with hematological diseases before hematopoietic stemcell transplantation. Methods The results and clinical data of 1 008 patients with hematological diseases in our hospital who underwent anti-HLA antibody testing were collected by using Luminex technology platform before transplantation from 2016 to 2018 for statistical analysis. Results The total positive rate of anti-HLA antibodies in 1 008 patients was 24.08%. Multivariate analysis showed that independent risk factors associated with the production of anti-HLA antibodies included age≥30 years old(P=0.046, OR1.467, 95%CI1.007-2.136), time from disease diagnosis to antibody testing≥41 days(P=0.000, OR1.830, 95%CI1.306-2.565), initial platelet count<20×109/L(P=0.020, OR1.543, 95%CI1.072-2.220), prior pregnancy(P=0.000, OR5.187, 95%CI3.689-7.293), transfusions before admission(P=0.001, OR1.762, 95%CI1.257-2.470)and total platelet transfusion volumes after admission≥30 U(P=0.000, OR2.352, 95%CI1.638-3.376). Age ≥30 years old(P=0.023, OR=1.839, 95%CI1.088-3.108)and prior pregnancy(P=0.042, OR=5.258, 95%CI1.062-26.038)are associated with the production of anti-HLA class Ⅰ and class Ⅱ antibodies, respectively. The time from disease diagnosis to antibody testing≥41 days(P=0.000, OR=2.873, 95%CI1.612-5.119), initial platelet count<20×109/L(P=0.008, OR=2.164, 95%CI1.225-3.822), prior pregnancy(P=0.002, OR=6.734, 95%CI1.993-22.751), transfusions before admission(P=0.001, OR=2.746, 95%CI1.531-4.925)and total platelet transfusion volumes after admission>30 U(P=0.006, OR=3.459, 95%CI1.416-8.451)are associated with the production of anti-HLA class Ⅰ and Ⅱ antibodies. Conclusion Older age, longer course of disease, lower PLT count, history of pregnancy and blood transfusion, and higher total amount of PLT transfusion are risk factors which affect the production of anti-HLA antibodies.Therefore, it is advisable to test for anti-HLA antibodies according to the situation before transplantation, which is of great value in guiding donor selection, monitoring antibody changes and improving transplant prognosis.
Authors and Affiliations
Kai JI, Lan WANG, Luyao CHEN, Xiaojing BAO, Xiaoni YUAN, Xiaojin WU, Jun HE
Keywords
Related Articles
- EP ID EP738761
- DOI 10.13303/j.cjbt.issn.1004549x.2024.02.007
- Views 84
- Downloads 0
Study on the changes of extracellular vesicle content of platelets at different storage periods, storage lesion and clinical efficacy
[Objective] To analyze the changes of platelet extracellular vesicles (PEVs) content in apheresis at different storage periods, track the PEVs and transfusion efficacy of patients, and explore the mechanism of PEVs in re...
Polymorphism study of HLA-A, B, DRB1 alleles in patients with chronic renal failure, in Shandong Peninsula
Objective To investigate the association between HLA-A, B, DRB1 alleles and chronic renal failure (CRF) in Han population of Shandong Peninsula. Methods Sequence specific oligonucleotide probe-polymerase chain reaction (...
Comparison of clinical efficacy of fibrinogen concentrate and cryoprecipitate on severe postpartum hemorrhage in puerpera with placenta accreta
Objective To explore the therapeutic effect of fibrinogen concentrate and cryoprecipitate on severe postpartum hemorrhage in puerpera with placenta accreta under the condition of transfusion of suspended red blood cells...
Correlation between unexpected antibody types and transfusion efficacy in patients with autoimmune hemolytic anemia (AIHA)
Objective To analyze the antibody types of autoimmune hemolytic anemia(AIHA) patients in Panyu district, Guangzhou and track the therapeutic effect of blood transfusion, so as to provide reference for clinical transfusio...
Progress in clinical application of autologous ozonized blood transfusion
Autologous ozonized blood transfusion (AOBT) is a therapeutic method that mixes blood with medical ozone in vitro and then reinfuses it into the body. It has been widely used in the auxiliary treatment of ischemia, hypox...